ATE225369T1 - Doppelsträngige peptidenukleinsäuren - Google Patents

Doppelsträngige peptidenukleinsäuren

Info

Publication number
ATE225369T1
ATE225369T1 AT94919803T AT94919803T ATE225369T1 AT E225369 T1 ATE225369 T1 AT E225369T1 AT 94919803 T AT94919803 T AT 94919803T AT 94919803 T AT94919803 T AT 94919803T AT E225369 T1 ATE225369 T1 AT E225369T1
Authority
AT
Austria
Prior art keywords
peptidenuclic
acids
double stranded
nucleic acids
peptide nucleic
Prior art date
Application number
AT94919803T
Other languages
English (en)
Inventor
Ole Buchardt
Michael Egholm
Peter E Nielsen
Rolf Berg
Benget Norden
Pernilla Wittung
Original Assignee
Buchardt Dorte
Michael Egholm
Nielsen Peter Eigil
Rolf Berg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buchardt Dorte, Michael Egholm, Nielsen Peter Eigil, Rolf Berg filed Critical Buchardt Dorte
Application granted granted Critical
Publication of ATE225369T1 publication Critical patent/ATE225369T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003Peptide-nucleic acids (PNAs)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/13Decoys
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/15Nucleic acids forming more than 2 strands, e.g. TFOs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/318Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181Peptide nucleic acid, PNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3513Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
AT94919803T 1993-07-02 1994-07-01 Doppelsträngige peptidenukleinsäuren ATE225369T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/088,661 US6228982B1 (en) 1992-05-22 1993-07-02 Double-stranded peptide nucleic acids
PCT/IB1994/000211 WO1995001369A1 (en) 1993-07-02 1994-07-01 Double-stranded peptide nucleic acids

Publications (1)

Publication Number Publication Date
ATE225369T1 true ATE225369T1 (de) 2002-10-15

Family

ID=22212671

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94919803T ATE225369T1 (de) 1993-07-02 1994-07-01 Doppelsträngige peptidenukleinsäuren

Country Status (7)

Country Link
US (2) US6228982B1 (de)
EP (1) EP0717750B1 (de)
JP (1) JPH09509435A (de)
AT (1) ATE225369T1 (de)
CA (1) CA2166462A1 (de)
DE (1) DE69431485T2 (de)
WO (1) WO1995001369A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US6277603B1 (en) 1991-12-24 2001-08-21 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5700922A (en) * 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US6770738B1 (en) * 1992-05-22 2004-08-03 Isis Pharmaceuticals, Inc. Higher order structure and binding of peptide nucleic acids
US7825215B1 (en) * 1993-04-26 2010-11-02 Peter E. Nielsen Substituted nucleic acid mimics
US6133444A (en) * 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
JPH10509947A (ja) * 1994-11-14 1998-09-29 カイロン コーポレイション サブモノマーアプローチによるペプチド核酸(pna▲下s▼)およびアナログの合成
JP2001518054A (ja) * 1995-06-07 2001-10-09 パーセプティブ バイオシステムズ,インコーポレーテッド Pna−dnaキメラと、このキメラ合成用のpnaシントン
EP0870055B1 (de) 1995-10-12 2007-05-16 LANSDORP, Peter, M. Verfahren zum nachweis von mehrfachkopien einer wiederholungssequenz in einem nukleinsäuremolekül
WO1997014793A1 (en) * 1995-10-20 1997-04-24 Trustees Of Boston University Nucleic acid clamps
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
EP0863150A1 (de) * 1997-02-08 1998-09-09 Boehringer Mannheim Gmbh Verfahren zur Herstellung einer Nukleinsäure-bindende Substanz
US6030997A (en) * 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
US20040186071A1 (en) * 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US20040063618A1 (en) * 2002-09-30 2004-04-01 Muthiah Manoharan Peptide nucleic acids having improved uptake and tissue distribution
DE19935302A1 (de) * 1999-07-28 2001-02-08 Aventis Pharma Gmbh Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen
WO2009003492A1 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
WO2003027328A2 (en) 2001-09-24 2003-04-03 Boston Probes, Inc. Methods, kits and compositions pertaining to the suppression of detectable probe binding to randomly distributed repeat sequences in genomic nucleic acid
JP2005520554A (ja) * 2002-03-21 2005-07-14 ボストン プローブス,インコーポレイテッド BacillusAnthracisの検出に関するPNAオリゴマー、オリゴマーセット、方法およびキット
US20030211509A1 (en) * 2002-03-26 2003-11-13 Wiley Steven R. TNF-delta ligand and uses thereof
KR20030084444A (ko) * 2002-04-26 2003-11-01 주식회사 파나진 Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
EP2161276A3 (de) * 2002-09-08 2010-05-26 Applera Corporation PNA enthaltende Verbindungen, Bibliotheken und Methoden und PNA Oligomersynthese
EP1631677B1 (de) * 2003-05-20 2010-11-17 Investigen, Inc. System zum nachweis von polynukleotiden
EP1745156A2 (de) * 2004-05-04 2007-01-24 Dako Denmark A/S Verfahren für den nachweis von chromosomenaberrationen
DE102004029011A1 (de) 2004-06-16 2006-01-12 Ems-Chemie Ag Polymermischung aus aliphatischen Polyamiden und teilaromatischen Polyamiden und deren Verwendung
WO2007044031A2 (en) * 2004-12-06 2007-04-19 Bioveris Corporation Methods and compositions for detecting bacillus anthracis
EP1893758B1 (de) 2005-06-20 2014-12-24 Oligomer Sciences AB Hybridisierung stabilisierendes konstrukt
WO2007045998A2 (en) 2005-07-01 2007-04-26 Dako Denmark A/S New nucleic acid base pairs
EP2010677A4 (de) * 2006-02-24 2010-04-14 Investigen Inc Verfahren und zusammensetzungen zum nachweis von polynukleotiden
US20080096193A1 (en) * 2006-10-24 2008-04-24 Charles Robert Bupp Methods and compositions for detecting polynucleotides
WO2008103702A2 (en) * 2007-02-23 2008-08-28 Investigen, Inc. Methods and compositions for rapid light-activated isolation and detection of analytes
EP2222851B1 (de) 2007-11-20 2017-06-28 Ionis Pharmaceuticals, Inc. Modulation der cd40-expression
EP2285979B2 (de) 2008-05-27 2020-02-19 Dako Denmark A/S Hybridisierungszusammensetzungen und -verfahren
US7964355B2 (en) * 2009-02-17 2011-06-21 Investigen, Inc. Assays based on detection of photobleaching reaction products from dye catalytic complex
US9303287B2 (en) 2009-02-26 2016-04-05 Dako Denmark A/S Compositions and methods for RNA hybridization applications
CA2781907C (en) 2009-12-02 2019-07-16 Dako Denmark A/S Compositions and methods for performing hybridizations with no denaturation
US9404160B2 (en) 2009-12-22 2016-08-02 Becton, Dickinson And Company Methods for the detection of microorganisms
EP2761028A1 (de) 2011-09-30 2014-08-06 Dako Denmark A/S Hybridisierungszusammensetzungen und -verfahren mit formamid
EP2768974B1 (de) 2011-10-21 2017-07-19 Dako Denmark A/S Hybridisierungszusammensetzungen und -verfahren
WO2014033314A1 (en) 2012-09-03 2014-03-06 Uab Bioseka Antisense oligonucleotide targeting bacterial glucosyltransferases
US20140178875A1 (en) 2012-10-09 2014-06-26 Advandx, Inc. Devices, Compositions and Methods Pertaining To Microscopic Analysis Of Microorganisms and Other Analytes of Interest
WO2014093291A1 (en) 2012-12-10 2014-06-19 Advandx, Inc. Use of probes for mass spectrometric identification of microorganisms or cells and associated conditions of interest
US10221216B2 (en) 2013-04-11 2019-03-05 Carnegie Mellon University Template-directed γPNA synthesis process and γPNA targeting compounds
US10370415B2 (en) 2013-04-11 2019-08-06 Carnegie Mellon University Divalent nucleobase compounds and uses therefor
LT6214B (lt) 2013-10-07 2015-08-25 Uab "Bioseka" Priešprasminiai oligonukleotidai aterosklerozės ir kardiovaskulinių infekcijų prevencijai
KR20160106684A (ko) 2014-01-10 2016-09-12 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 히드록시포름아미드 유도체 및 그의 용도
US10851407B2 (en) 2014-05-08 2020-12-01 Carnegie Mellon University Left-handed gamma-peptide nucleic acids, methods of synthesis and uses therefor
EP3370518B1 (de) 2015-10-14 2023-08-23 X-Therma, Inc. Zusammensetzungen und verfahren zur verringerung der eiskristallbildung
CA3033474C (en) 2016-08-09 2023-09-19 Seasun Therapeutics Peptide nucleic acid complex having improved cell permeability and pharmaceutical composition comprising same
JP2019531726A (ja) 2016-09-26 2019-11-07 カーネギー メロン ユニバーシティ 二価核酸塩基化合物およびそれらの使用
KR102262260B1 (ko) * 2018-02-08 2021-06-09 주식회사 시선테라퓨틱스 엔도좀 탈출능을 갖는 펩티드 핵산 복합체 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE171185T1 (de) * 1985-03-15 1998-10-15 Antivirals Inc Immunotestmittel für polynukleotid und verfahren
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
MX9207334A (es) * 1991-12-18 1993-08-01 Glaxo Inc Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene

Also Published As

Publication number Publication date
WO1995001369A1 (en) 1995-01-12
EP0717750B1 (de) 2002-10-02
JPH09509435A (ja) 1997-09-22
CA2166462A1 (en) 1995-01-12
DE69431485D1 (de) 2002-11-07
DE69431485T2 (de) 2003-01-30
EP0717750A1 (de) 1996-06-26
US6610650B1 (en) 2003-08-26
US6228982B1 (en) 2001-05-08

Similar Documents

Publication Publication Date Title
ATE225369T1 (de) Doppelsträngige peptidenukleinsäuren
ATE205504T1 (de) Peptidnukleinsäuren
EP1310507A3 (de) Neue Peptid-Nukleinsäuren
ES2181799T3 (es) Conjugados de acidos peptido nucleicos.
CA2153898A1 (en) Method for generating single-stranded dna molecules
DE69611102D1 (de) Verstärkung der mutagenese von nukleinsäuren
AU6589094A (en) 7-deazapurine modified oligonucleotides
FI970832A (fi) Biologisen materiaalin, kuten nukleiinihapon, erottamiseen käytettävä laite
IT1226123B (it) Turbopompa molecolare.
DE69634077D1 (de) Haemophilus adhäsionsproteinen
MX9806041A (es) Proteina purificada sr-p70.
EA199900893A1 (ru) Бактериальные плазмиды
CA2287902A1 (en) Isolated nucleic acid molecules encoding ssx family members and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties